May 2026 SCRI Release Notes Copied
The following updates were completed between April 17 – May 14, 2026. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.
For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 24198 | USOR 24198 AML 82 Phase 3 Bleximenib or Placebo + Venetoclax + Azacitidine Q28D – 24SEP2025
USOR 24198 AML 82 Phase 3 Maintenance Bleximenib or Placebo Q28D – 24SEP2025 |
| 25006 | USOR 25006 GI 408 Phase 3 Arm A Rechallenge Tremelimumab + Rilvegostomig + Bevacizumab Q21D – v1.0 04DEC2024
USOR 25006 GI 408 Phase 3 Arm A Tremelimumab + Rilvegostomig + Bevacizumab Q21D – v1.0 04DEC2024 USOR 25006 GI 408 Phase 3 Arm B Rilvegostomig + Bevacizumab Q21D – v1.0 04DEC2024 USOR 25006 GI 408 Phase 3 Arm C Atezolizumab + Bevacizumab Q21D – v1.0 04DEC2024 |
| 25020 | USOR 25020 GYN 155 Phase 3 Arm A T-DXd Q21D – v2.0 30JUN2025
USOR 25020 GYN 155 Phase 3 Arm B EBRT + Cisplatin D1,29 – v2.0 30JUN2025 USOR 25020 GYN 155 Phase 3 Arm B Paclitaxel (or Docetaxel) + Carboplatin Q21D – v2.0 30JUN2025 |
| 25080 | USOR 25080 GYN 158 Phase 3 Part 1 Sacituzumab Tirumotecan + Pembrolizumab + Bevacizumab Q42D – 05DEC2025 |
| 25097 | USOR 25097 MDS 39 Phase 3 Elritercept or Placebo Q28D – 23JUN2025 |
| 25111 | USOR 25111 GU 289 Phase 2 Arm A Izalontamab Brengitecan Q21D – v1.0 20MAY2025
USOR 25111 GU 289 Phase 2 Arm B Izalontamab Brengitecan Q21D – v1.0 20MAY2025 USOR 25111 GU 289 Phase 2 Arm C Gemcitabine + Carboplatin Q21D – v1.0 20MAY2025 USOR 25111 GU 289 Phase 2 Arm C Gemcitabine + Cisplatin Q21D – v1.0 20MAY2025 |
| 25123 | USOR 25123 GU 294 Phase 3 Docetaxel Q42D – 15SEP2025
USOR 25123 GU 294 Phase 3 Pasritamig + Docetaxel Q42D – 15SEP2025 USOR 25123 GU 294 Phase 3 Pasritamig + Docetaxel Q56D – 15SEP2025 |
| 25124 | USOR 25124 LUN 638 Phase 2 ABBV-706 + Atezolizumab Q21D – v2.0 01Oct2025
USOR 25124 LUN 638 Phase 2 Atezolizumab + Carboplatin + Etoposide Q21D – v2.0 01Oct2025 USOR 25124 LUN 638 Phase 2 Atezolizumab + Lurbinectedin maintenance Q21D – v2.0 01Oct2025 USOR 25124 LUN 638 Phase 2 Atezolizumab maintenance Q21D – v2.0 01Oct2025 |
| 25146 | USOR 25146 MULTI 106 Phase 1b Cohort 1A AMXT 1501 + DFMO + Capivasertib + Fulvestrant Q28D – v3.0 04SEP2025
USOR 25146 MULTI 106 Phase 1b Cohort 2A AMXT 1501 + DFMO + Pembrolizumab Q21D – v3.0 04SEP2025 |
| 25147 | USOR 25147 GI 427 Phase 3 D07001 or Placebo + Capecitabine Q21D – v4.0 22OCT2025 |
| 25178 | USOR 25178 MPN 27 Phase 3 Arm A Bomedemstat Q14D – 08SEP2025
USOR 25178 MPN 27 Phase 3 Arm B Anagrelide Q30D – 08SEP2025 USOR 25178 MPN 27 Phase 3 Arm B Busulfan Q30D – 08SEP2025 USOR 25178 MPN 27 Phase 3 Arm B Pegylated interferon alfa 2a Q7D – 08SEP2025 USOR 25178 MPN 27 Phase 3 Arm B Ruxolitinib Q30D – 08SEP2025 |
| 25190 | USOR 25190 ALL 14 Phase 2 Lymphodepletion Fludarabine (D-6,-5,-4,-3) + Cyclophosphamide (D-5,-4,-3) – 18JUN2025
USOR 25190 ALL 14 Phase 2 WU-CART-007 Day 0 – 18JUN2025 |
| 25192 | USOR 25192 MPN 29 Phase 3 Bomedemstat or Placebo + Hydroxyurea or Placebo Q28D – 07MAY2025 |
| 25204 | USOR 25204 GYN 145 Phase 1b R-DXd + Bevacizumab Q21D – 30SEP2025
USOR 25204 GYN 145 Phase 1b R-DXd + Carboplatin Q21D – 30SEP2025 USOR 25204 GYN 145 Phase 1b R-DXd + Paclitaxel Q21D – 30SEP2025 USOR 25204 GYN 145 Phase 1b R-DXd + Pembrolizumab Q21D – 30SEP2025 |
| 25230 | USOR 25230 GU 311 Phase 3 Arm 1 BNT324 Q21D – v2.0 22DEC2025
USOR 25230 GU 311 Phase 3 Arm 2 Docetaxel + Prednisone Q21D – v2.0 22DEC2025 |
| 25235 | USOR 25235 GU 312 Phase 3 Arm A Enfortumab vedotin + Pembrolizumab Q21D – 10FEB2026
USOR 25235 GU 312 Phase 3 Arm A Maintenance Pembrolizumab Q21D – 10FEB2026 USOR 25235 GU 312 Phase 3 Arm B Cisplatin + XRT Q7D – 10FEB2026 USOR 25235 GU 312 Phase 3 Arm B Fluorouracil + Mitomycin + XRT Q27D – 10FEB2026 USOR 25235 GU 312 Phase 3 Arm B Gemcitabine + XRT Q7D – 10FEB2026 |
| 25238 | USOR 25238 GI 449 Phase 3 Atebimetinib + Nab-Paclitaxel + Gemcitabine Q28D – v2.0 23FEB2026
USOR 25238 GI 449 Phase 3 Nab-Paclitaxel + Gemcitabine Q28D – v2.0 23FEB2026 |
| 25239 | USOR 25239 BRE 483 Phase 1b Cohort A Sapanisertib + Serabelisib + Fulvestrant Q28D – v1.0 17DEC2025
USOR 25239 BRE 483 Phase 1b Cohort B Sapanisertib + Serabelisib + Fulvestrant + Palbociclib Q28D – v1.0 17DEC2025 |
| RM 1204
MCCR |
RM 1204 Phase 1 Part A CLSP-1025 (with C1 off-site documentation) Q28D – v2.0 18DEC2024 |
| GU 300
MCCR |
GU 300 Phase 1 Part 1A Arm A INR731 Q28D – v02 13MAR2026 |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes |
| 25090 | Version 3.0; 14th November 2025 | N/A | N/A | Update Drug; Dose/Form
Closed Arm(s) |
| 25080 | PM v4.0; 12-March-2026 | N/A | N/A | Update Drug; Instructions |
| 25070 | Version 6.1; 30th January 2026 | N/A | Regimen comments; premedication | Update drug; premedication.
New Arms |
| 25040 | PM v3.0; 23-March-2026 | N/A | N/A | Update drug; instructions |
| 25021 | Amendment 1.0; 24-Sept-2025 | N/A | Regimen comments; administration, observation | Update drug; instructions |
| 25017 | Version 1.0; 6th January 2026 | N/A | N/A | Update drug; instructions |
| 24292 | Adding Tocilizumab: Congruency Chat | N/A | N/A | Added drug |
| 24265 | PM v6.0; 03-April-2026 | N/A | N/A | Update drug; instructions |
| 24211 | Version 10.0; 14 October 2025 | N/A | N/A | Added; drug
New Arms |
| 24211 | PM v6.0; 4th December 2025 | N/A | N/A | Added; drug |
| 23294 | Version 6.0; 07 October 2025 | N/A | Regimen comments; administration, premedication | Update drug; instructions |
| 23087 | Amendment 4; 11-March-2026 | N/A | Regimen comments; prophylaxis | Update drug; instructions, premedication |
| 22067 | Version 6.0; 20 October 2025 | N/A | Regimen comments; premedication | Update drug; instructions |
| 21462 | PM v8.0; 8-December-2025 | N/A | Regimen comments; premedication | N/A |
| 20248 | OLE Arm only | N/A | Regimen comments; Administration | Update drug; instructions |
| RM 1275
MCCR |
PM v4: 16 Mar 2026 | N/A | N/A | Update drug; instructions, name |
| 24164 | Version 2.2: 29 August 2025 (+ new PM v4.0) | N/A | Regimen comments; Administration | Update drug; instructions |
| 25044 | PM 2.0; 19-Sept-2025
PM v3.0; 22-Aug-2025 PM v4.0; 01-Aug-2025 |
N/A | N/A | Update drug; instructions |
| 24098 | Version 2.0; 12-March-2026 | N/A | Regimen Comments; administration | Update drug; instructions |